{"gene":"TLK2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"TLK2 (PKU-alpha) encodes a serine/threonine protein kinase with a C-terminal kinase domain and a putative nuclear localization signal (NLS) in its N-terminal region. GST-fusion proteins containing the NLS were efficiently localized to the nucleus, establishing nuclear targeting as a functional property of the NLS.","method":"cDNA cloning, bacteriophage expression library screening for kinase activity, GST-fusion nuclear localization assay, transient transfection in COS-1 cells","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical assay (kinase activity) plus subcellular localization experiment; single lab, two orthogonal methods","pmids":["9427565"],"is_preprint":false},{"year":2016,"finding":"TLK2 amplification and overexpression mechanistically impairs Chk1/Chk2-induced DNA damage checkpoint signaling, leading to a G2-M checkpoint defect, delayed DNA repair, and increased chromosomal instability (CIN). TLK2 overexpression also modestly sensitizes breast cancer cells to DNA-damaging agents.","method":"TLK2 overexpression/knockdown in breast cancer cell lines, G2-M checkpoint assays, DNA damage signaling (Chk1/2 phosphorylation), DNA repair kinetics, irradiation/doxorubicin sensitivity assays","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based loss- and gain-of-function with defined checkpoint phenotype; single lab, multiple orthogonal readouts","pmids":["27489360"],"is_preprint":false},{"year":2018,"finding":"Loss-of-function mutations in TLK2 act through haploinsufficiency, as demonstrated in cell lines from affected individuals, establishing the mechanistic basis for the associated neurodevelopmental syndrome.","method":"Cell line analysis from affected individuals, functional assessment of mutation effect on TLK2 activity","journal":"American journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — loss-of-function mechanism asserted from cell lines but abstract provides limited methodological detail; single study","pmids":["29861108"],"is_preprint":false},{"year":2019,"finding":"TLK2 is a substrate of the circadian E3 ligase complex SCFFBXL3+CRY1/2: both CRY1 and CRY2 recruit TLK2 to SCFFBXL3, and TLK2 kinase activity is required for this interaction. Overexpression of CRY1/2 decreases TLK2 protein abundance, while genetic deletion of CRY1/2 enhances it, demonstrating CRY-modulated ubiquitin-mediated turnover of TLK2.","method":"Affinity purification mass spectrometry (APMS), CRY1/2 overexpression and genetic deletion, TLK2 protein abundance measurements","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — APMS substrate identification combined with genetic gain- and loss-of-function validation of protein abundance; single lab, two orthogonal approaches","pmids":["30655559"],"is_preprint":false},{"year":2020,"finding":"Disease-associated TLK2 missense variants (p.Asp551Gly and p.Ser617Leu) strongly impair TLK2 kinase activity. Proximity interaction (BioID) mapping revealed TLK2 interacts with chromatin remodeling factors CHD7, CHD8, BRD4, and NACC1. Cells harboring p.Asp551Gly show a more relaxed chromatin state and increased susceptibility to DNA damage.","method":"BioID spatial proteomics (proximity ligation), in vitro kinase activity assay of TLK2 variants, single-cell gel electrophoresis (comet assay) for DNA damage, chromatin accessibility analysis","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct kinase activity assay plus BioID interactome and functional chromatin/DNA damage readout; single lab, multiple orthogonal methods","pmids":["33323470"],"is_preprint":false},{"year":2024,"finding":"TLK1 and TLK2 undergo hyper-autophosphorylation at their N-termini, mediated at least in part by homo- or hetero-dimerization. This hyper-autophosphorylation masks a conserved non-canonical PIP box at the N-terminus, negatively regulating TLK2 recruitment to DNA damage sites. Mutation of the PIP box abolishes TLK1/2 recruitment to DNA damage foci, establishing the PIP box–PCNA interaction as the mechanism for chromatin recruitment.","method":"In vitro autophosphorylation assays, PIP-box mutagenesis, PCNA co-immunoprecipitation, live-cell imaging of recruitment to DNA damage sites","journal":"Nucleic acids research (also preprint in bioRxiv)","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro biochemical assays combined with mutagenesis and direct damage-site recruitment imaging; peer-reviewed and preprint versions independently described","pmids":["39727191","38712247"],"is_preprint":false},{"year":2025,"finding":"TLK2 functions as a key regulator of chromatin loop formation during cancer stemness transitions. Mechanistically, TLK2 phosphorylates DYNLL1 (LC8), enhancing DYNLL1 interaction with CTCF and promoting CTCF-cohesin hub formation at the KLF4 locus.","method":"CRISPR screen using engineered live-cell CTCF-cohesin contact reporters, phosphorylation assays of DYNLL1 by TLK2, Co-IP of DYNLL1–CTCF interaction, chromatin loop analysis at KLF4 locus, in vivo mouse models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — CRISPR functional screen combined with direct substrate phosphorylation assay and protein interaction validation by Co-IP; single study with multiple orthogonal methods","pmids":["41120304"],"is_preprint":false},{"year":2025,"finding":"Calcium overload increases TLK2 expression, multimerization, and phosphorylation, enhancing its kinase activity in neurons. Elevated TLK2 activity triggers nuclear envelope (NE) rupture, nuclear enlargement, multinucleation, and cell cycle reentry markers. A protein complex involving TLK2, dynein light chain LC8, and myosin IIA was linked to NE disruption. TLK2 inhibition (RNAi or small-molecule inhibitor) reduces neuronal death in this context.","method":"RNA interference, small-molecule TLK2 inhibition, overexpression, live-cell imaging of nuclear envelope rupture, co-immunoprecipitation (TLK2–LC8–myosin IIA complex), mouse glaucoma model with retinal ganglion cell degeneration readout","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (RNAi, small-molecule inhibition, overexpression, complex identification by Co-IP, in vivo model) in single peer-reviewed study","pmids":["40210858"],"is_preprint":false},{"year":2023,"finding":"TLK2 knockdown in gastric cancer cells suppresses amino acid synthesis by downregulating the mTORC1 pathway and ASNS expression. TLK2 directly interacts with ATF4 (a transcription factor of ASNS) and promotes its expression. mTORC1 directly interacts with ASNS protein and inhibits its ubiquitination-mediated degradation.","method":"IP-MS (interactome identification), TLK2 knockdown/overexpression, mTORC1 pathway analysis, co-immunoprecipitation (TLK2–ATF4; mTORC1–ASNS), ubiquitination assays, fostamatinib TLK2 kinase inhibition","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and IP-MS with functional pathway validation; single lab, multiple methods","pmids":["37542132"],"is_preprint":false},{"year":2018,"finding":"TLK2 overexpression in glioblastoma activates SRC signaling, driving cell growth, migration, invasion, and EMT. Inhibition of SRC signaling with saracatinib reverses TLK2-mediated migration and invasion, placing TLK2 upstream of SRC pathway in glioblastoma.","method":"TLK2 overexpression/knockdown in glioblastoma cells, cell migration/invasion assays, SRC pathway inhibition with saracatinib","journal":"Cancer biology & therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological epistasis with single inhibitor, no direct biochemical interaction demonstrated; single lab, single method for pathway placement","pmids":["30207834"],"is_preprint":false},{"year":2026,"finding":"In postmitotic neurons, TLK2 undergoes nuclear export upon neuronal differentiation, generating a predominantly cytoplasmic pool. This is mediated by two mechanisms: nuclear export of full-length TLK2 and increased expression of TLK2 splice variants lacking the NLS. Acute stimuli mimicking synaptic activity are sufficient to trigger nuclear export of TLK2, establishing activity-driven nucleocytoplasmic shuttling as a neuronal-specific regulatory mechanism.","method":"In situ hybridization with splice-specific probes in mouse brain sections, subcellular fractionation and immunostaining in rat neuroblastoma cells during differentiation, live imaging of TLK2 localization after synaptic stimulation","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with functional differentiation context and splice variant characterization; single lab, two orthogonal localization methods","pmids":["42023051"],"is_preprint":false}],"current_model":"TLK2 is a nuclear-localized serine/threonine kinase (with activity-driven cytoplasmic redistribution in neurons) that autophosphorylates at its N-terminus via homo/heterodimerization, masking a PIP box to negatively regulate PCNA-dependent recruitment to DNA damage sites; it is ubiquitinated and turned over via the SCFFBXL3+CRY1/2 E3 ligase complex (requiring TLK2 kinase activity for substrate recruitment); TLK2 phosphorylates DYNLL1 to drive CTCF-cohesin chromatin loop formation; TLK2 overexpression impairs Chk1/2-mediated G2-M checkpoint signaling causing chromosomal instability; and calcium overload activates TLK2 kinase activity through multimerization, forming a complex with LC8 and myosin IIA that ruptures the nuclear envelope in a distinct neuronal death pathway."},"narrative":{"mechanistic_narrative":"TLK2 is a nuclear serine/threonine protein kinase that couples its catalytic activity to chromatin regulation, DNA damage responses, and cell-fate decisions [PMID:9427565, PMID:39727191, PMID:38712247]. Its recruitment to chromatin is gated by autoregulation: TLK2 hyper-autophosphorylates its N-terminus through homo- and hetero-dimerization with TLK1, masking a non-canonical PIP box that mediates PCNA-dependent recruitment to DNA damage sites [PMID:39727191, PMID:38712247]. Functionally, TLK2 organizes higher-order chromatin by phosphorylating DYNLL1 (LC8), which enhances DYNLL1–CTCF binding and promotes CTCF–cohesin loop/hub formation at the KLF4 locus during cancer stemness transitions [PMID:41120304], and it associates in proximity with the chromatin remodelers CHD7, CHD8, BRD4, and NACC1 [PMID:33323470]. TLK2 abundance is controlled by ubiquitin-mediated turnover through the circadian E3 ligase SCFFBXL3 via CRY1/2, a recruitment that depends on TLK2 kinase activity [PMID:30655559]. Through these activities TLK2 enforces genome stability, since its overexpression impairs Chk1/Chk2 G2-M checkpoint signaling, delays repair, and drives chromosomal instability [PMID:27489360], while loss-of-function and kinase-dead missense variants relax chromatin and increase DNA damage susceptibility, acting through haploinsufficiency to cause a neurodevelopmental syndrome [PMID:29861108, PMID:33323470]. In neurons, TLK2 is regulated by activity-driven nucleocytoplasmic shuttling [PMID:42023051], and calcium overload activates TLK2 via multimerization to form a complex with LC8 and myosin IIA that ruptures the nuclear envelope in a degenerative death pathway [PMID:40210858].","teleology":[{"year":1997,"claim":"Established TLK2's basic identity, answering whether the gene encodes a functional kinase and where it acts by identifying catalytic activity and a functional nuclear localization signal.","evidence":"cDNA cloning with kinase-activity expression screening and GST-fusion nuclear localization assay in COS-1 cells","pmids":["9427565"],"confidence":"Medium","gaps":["No substrates identified","No physiological pathway context","NLS function shown only for an isolated GST fusion"]},{"year":2016,"claim":"Linked TLK2 dosage to genome maintenance by showing that its overexpression disrupts checkpoint signaling, framing TLK2 as a driver of chromosomal instability in cancer.","evidence":"Gain- and loss-of-function in breast cancer lines with G2-M checkpoint, Chk1/2 phosphorylation, repair kinetics, and DNA-damage sensitivity readouts","pmids":["27489360"],"confidence":"Medium","gaps":["Direct kinase substrate in the checkpoint pathway not identified","Mechanism connecting TLK2 to Chk1/2 unresolved","Single cancer-cell context"]},{"year":2018,"claim":"Defined the genetic mechanism of TLK2-associated disease, showing that loss-of-function variants cause a neurodevelopmental syndrome through haploinsufficiency.","evidence":"Functional assessment of patient-derived cell lines carrying TLK2 mutations","pmids":["29861108"],"confidence":"Low","gaps":["Limited methodological detail in the source","Molecular pathway linking haploinsufficiency to neurodevelopmental phenotype not defined","Single study"]},{"year":2018,"claim":"Placed TLK2 upstream of an oncogenic signaling axis by showing it activates SRC to drive glioblastoma migration and invasion.","evidence":"Overexpression/knockdown with migration/invasion assays and SRC inhibition by saracatinib","pmids":["30207834"],"confidence":"Low","gaps":["Pharmacological epistasis only — no direct biochemical link to SRC","No demonstrated phosphorylation target","Single inhibitor used for pathway placement"]},{"year":2019,"claim":"Identified how TLK2 protein levels are controlled, showing it is a kinase-activity-dependent substrate of the circadian SCFFBXL3+CRY1/2 ubiquitin ligase.","evidence":"APMS substrate identification plus CRY1/2 overexpression and genetic deletion with TLK2 abundance measurements","pmids":["30655559"],"confidence":"Medium","gaps":["Ubiquitination sites on TLK2 not mapped","Physiological consequence of circadian TLK2 oscillation not tested","Whether kinase activity drives autoturnover unexplored"]},{"year":2020,"claim":"Connected disease variants to molecular dysfunction by showing missense mutations abolish kinase activity and that TLK2 sits in a chromatin-remodeler interactome controlling chromatin compaction.","evidence":"In vitro kinase assays of variants, BioID proximity interactome, comet assay, and chromatin accessibility analysis","pmids":["33323470"],"confidence":"Medium","gaps":["Direct substrates among CHD7/CHD8/BRD4/NACC1 not established","Whether proximity partners are phosphorylated by TLK2 unknown","Causal chain from kinase loss to chromatin relaxation incomplete"]},{"year":2024,"claim":"Resolved the mechanism gating TLK2 chromatin recruitment, showing autophosphorylation masks a PIP box required for PCNA-dependent recruitment to damage sites.","evidence":"In vitro autophosphorylation assays, PIP-box mutagenesis, PCNA Co-IP, and live-cell imaging of damage-site recruitment","pmids":["39727191","38712247"],"confidence":"High","gaps":["Dynamics of de-repression at damage sites not defined","Downstream chromatin substrates at damage foci not identified","Relative roles of TLK1 vs TLK2 dimers unresolved"]},{"year":2025,"claim":"Defined a direct catalytic output of TLK2 in genome architecture, showing it phosphorylates DYNLL1 to promote CTCF-cohesin loop formation governing cancer stemness.","evidence":"CRISPR screen with live-cell CTCF-cohesin reporters, DYNLL1 phosphorylation assays, DYNLL1–CTCF Co-IP, loop analysis at KLF4, and mouse models","pmids":["41120304"],"confidence":"High","gaps":["DYNLL1 phosphosite(s) not detailed in this synthesis","Generality beyond the KLF4 locus unclear","Link between this loop function and DNA-damage role unexplored"]},{"year":2025,"claim":"Uncovered a pathological neuronal function, showing calcium-driven TLK2 multimerization and activity form an LC8–myosin IIA complex that ruptures the nuclear envelope to drive neuronal death.","evidence":"RNAi, small-molecule inhibition, overexpression, live imaging of NE rupture, TLK2–LC8–myosin IIA Co-IP, and a mouse glaucoma RGC degeneration model","pmids":["40210858"],"confidence":"High","gaps":["Direct kinase substrate driving NE rupture not identified","How calcium triggers multimerization mechanistically unknown","Relationship to TLK2's chromatin functions unresolved"]},{"year":2026,"claim":"Established neuron-specific spatial regulation of TLK2, showing differentiation and synaptic activity drive its nuclear export and NLS-lacking splice variants generate a cytoplasmic pool.","evidence":"Splice-specific in situ hybridization in mouse brain, subcellular fractionation/immunostaining during neuroblastoma differentiation, and live imaging after synaptic stimulation","pmids":["42023051"],"confidence":"Medium","gaps":["Cytoplasmic substrates of exported TLK2 not identified","Export machinery not defined","Functional consequence of activity-driven shuttling untested"]},{"year":2023,"claim":"Implicated TLK2 in metabolic control, showing it interacts with ATF4 to promote ASNS expression and amino-acid synthesis via mTORC1 in gastric cancer.","evidence":"IP-MS, knockdown/overexpression, TLK2–ATF4 and mTORC1–ASNS Co-IP, ubiquitination assays, and TLK2 kinase inhibition","pmids":["37542132"],"confidence":"Medium","gaps":["Whether TLK2 phosphorylates ATF4 not shown","Direct vs indirect mTORC1 regulation unresolved","Single cancer-cell context"]},{"year":null,"claim":"How TLK2's distinct activities — DNA-damage recruitment, CTCF-cohesin looping, circadian turnover, neuronal nuclear-envelope rupture, and metabolic signaling — are coordinated by a single kinase, and what its full substrate repertoire is, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["A unifying substrate logic across contexts is undefined","Tissue-specific regulation of which function dominates is unknown","Structural basis of activity-dependent multimerization vs dimerization unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[5,6]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,4,6]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,10]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[10,7]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[5,6]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[5,1]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,6]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1]}],"complexes":["SCFFBXL3-CRY1/2 E3 ligase (substrate)","TLK2-LC8-myosin IIA complex"],"partners":["DYNLL1","PCNA","CRY1","CRY2","CHD7","CHD8","BRD4","ATF4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86UE8","full_name":"Serine/threonine-protein kinase tousled-like 2","aliases":["HsHPK","PKU-alpha","Tousled-like kinase 2"],"length_aa":772,"mass_kda":87.7,"function":"Serine/threonine-protein kinase involved in the process of chromatin assembly and probably also DNA replication, transcription, repair, and chromosome segregation (PubMed:10523312, PubMed:11470414, PubMed:12660173, PubMed:12955071, PubMed:29955062, PubMed:33323470, PubMed:9427565). Phosphorylates the chromatin assembly factors ASF1A and ASF1B (PubMed:11470414, PubMed:20016786, PubMed:29955062, PubMed:35136069). Phosphorylation of ASF1A prevents its proteasome-mediated degradation, thereby enhancing chromatin assembly (PubMed:20016786). Negative regulator of amino acid starvation-induced autophagy (PubMed:22354037)","subcellular_location":"Nucleus; Nucleus, nucleoplasm; Cytoplasm, perinuclear region; Cytoplasm, cytoskeleton","url":"https://www.uniprot.org/uniprotkb/Q86UE8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/TLK2","classification":"Common Essential","n_dependent_lines":808,"n_total_lines":1208,"dependency_fraction":0.6688741721854304},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000146872","cell_line_id":"CID001290","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"nuclear_punctae","grade":1}],"interactors":[{"gene":"TLK1","stoichiometry":10.0},{"gene":"DYNLL1","stoichiometry":0.2},{"gene":"DYNLL2","stoichiometry":0.2},{"gene":"PSMD9","stoichiometry":0.2},{"gene":"H1F0","stoichiometry":0.2},{"gene":"DYNLL1;DYNLL2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001290","total_profiled":1310},"omim":[{"mim_id":"618050","title":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 57; MRD57","url":"https://www.omim.org/entry/618050"},{"mim_id":"609190","title":"ANTI-SILENCING FUNCTION 1B HISTONE CHAPERONE; ASF1B","url":"https://www.omim.org/entry/609190"},{"mim_id":"609189","title":"ANTI-SILENCING FUNCTION 1A HISTONE CHAPERONE; ASF1A","url":"https://www.omim.org/entry/609189"},{"mim_id":"608439","title":"TOUSLED-LIKE KINASE 2; TLK2","url":"https://www.omim.org/entry/608439"},{"mim_id":"608438","title":"TOUSLED-LIKE KINASE 1; TLK1","url":"https://www.omim.org/entry/608438"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TLK2"},"hgnc":{"alias_symbol":["PKU-ALPHA","MGC44450"],"prev_symbol":[]},"alphafold":{"accession":"Q86UE8","domains":[{"cath_id":"3.30.200.20","chopping":"452-546","consensus_level":"high","plddt":91.2152,"start":452,"end":546},{"cath_id":"1.10.510.10","chopping":"553-738","consensus_level":"high","plddt":93.9419,"start":553,"end":738},{"cath_id":"1.10.287","chopping":"272-347_400-450","consensus_level":"medium","plddt":92.3598,"start":272,"end":450}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86UE8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86UE8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86UE8-F1-predicted_aligned_error_v6.png","plddt_mean":71.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TLK2","jax_strain_url":"https://www.jax.org/strain/search?query=TLK2"},"sequence":{"accession":"Q86UE8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86UE8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86UE8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86UE8"}},"corpus_meta":[{"pmid":"29861108","id":"PMC_29861108","title":"De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder.","date":"2018","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29861108","citation_count":40,"is_preprint":false},{"pmid":"27489360","id":"PMC_27489360","title":"Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27489360","citation_count":28,"is_preprint":false},{"pmid":"30655559","id":"PMC_30655559","title":"The circadian E3 ligase complex SCFFBXL3+CRY targets TLK2.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30655559","citation_count":25,"is_preprint":false},{"pmid":"12203774","id":"PMC_12203774","title":"Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the ACCN1 and TLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients.","date":"2002","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12203774","citation_count":20,"is_preprint":false},{"pmid":"33323470","id":"PMC_33323470","title":"Functional analysis of TLK2 variants and their proximal interactomes implicates impaired kinase activity and chromatin maintenance defects in their pathogenesis.","date":"2020","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33323470","citation_count":17,"is_preprint":false},{"pmid":"30207834","id":"PMC_30207834","title":"TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway.","date":"2018","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30207834","citation_count":17,"is_preprint":false},{"pmid":"31558842","id":"PMC_31558842","title":"Severe neurodevelopmental disease caused by a homozygous TLK2 variant.","date":"2020","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/31558842","citation_count":15,"is_preprint":false},{"pmid":"37542132","id":"PMC_37542132","title":"Targeting TLK2 inhibits the progression of gastric cancer by reprogramming amino acid metabolism through the mTOR/ASNS axis.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37542132","citation_count":12,"is_preprint":false},{"pmid":"9427565","id":"PMC_9427565","title":"cDNA cloning and chromosomal mapping of genes encoding novel protein kinases termed PKU-alpha and PKU-beta, which have nuclear localization signal.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9427565","citation_count":12,"is_preprint":false},{"pmid":"36134026","id":"PMC_36134026","title":"Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36134026","citation_count":5,"is_preprint":false},{"pmid":"40210858","id":"PMC_40210858","title":"A TLK2-mediated calcium-driven cell death pathway links neuronal degeneration to nuclear envelope disruption.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40210858","citation_count":4,"is_preprint":false},{"pmid":"41120304","id":"PMC_41120304","title":"Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41120304","citation_count":4,"is_preprint":false},{"pmid":"38636130","id":"PMC_38636130","title":"Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38636130","citation_count":2,"is_preprint":false},{"pmid":"39538191","id":"PMC_39538191","title":"Report of one case with de novo mutation in TLK2 and literature review.","date":"2024","source":"BMC pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/39538191","citation_count":1,"is_preprint":false},{"pmid":"38926950","id":"PMC_38926950","title":"[Effect of TLK2 Expression Regulated by MiR-21 on Proliferation and Apoptosis of Acute Myeloid Leukemia Cells].","date":"2024","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/38926950","citation_count":1,"is_preprint":false},{"pmid":"39296544","id":"PMC_39296544","title":"Case report: A novel TLK2 variant with a neuropsychiatric phenotype from a Chinese family.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39296544","citation_count":1,"is_preprint":false},{"pmid":"38712247","id":"PMC_38712247","title":"Autophosphorylation of the Tousled-like kinases TLK1 and TLK2 regulates recruitment to damaged chromatin via PCNA interaction.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38712247","citation_count":1,"is_preprint":false},{"pmid":"39727191","id":"PMC_39727191","title":"Autophosphorylation of the Tousled-like kinases TLK1 and TLK2 regulates recruitment to damaged chromatin via PCNA interaction.","date":"2025","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/39727191","citation_count":0,"is_preprint":false},{"pmid":"39145094","id":"PMC_39145094","title":"TLK2 promotes progression of hepatocellular carcinoma through Wnt/β-catenin signaling.","date":"2024","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39145094","citation_count":0,"is_preprint":false},{"pmid":"38234837","id":"PMC_38234837","title":"Discovery and Optimization of Narrow Spectrum Inhibitors of Tousled Like Kinase 2 (TLK2) Using Quantitative Structure Activity Relationships.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38234837","citation_count":0,"is_preprint":false},{"pmid":"42023051","id":"PMC_42023051","title":"Neuronal differentiation and activity drive nucleocytoplasmic shuttling of the intellectual disability kinase TLK2.","date":"2026","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/42023051","citation_count":0,"is_preprint":false},{"pmid":"38500246","id":"PMC_38500246","title":"Exploring the role of TLK2 mutation in tropical calcific pancreatitis: an in silico and molecular dynamics simulation study.","date":"2024","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/38500246","citation_count":0,"is_preprint":false},{"pmid":"41878536","id":"PMC_41878536","title":"Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41878536","citation_count":0,"is_preprint":false},{"pmid":"41931014","id":"PMC_41931014","title":"Expanding the Phenotype of TLK2-Related Neurodevelopmental Disorder: Longitudinal Presentation in Two Young Adult Females.","date":"2026","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41931014","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13335,"output_tokens":3134,"usd":0.043507,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10625,"output_tokens":4075,"usd":0.0775,"stage2_stop_reason":"end_turn"},"total_usd":0.121007,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TLK2 (PKU-alpha) encodes a serine/threonine protein kinase with a C-terminal kinase domain and a putative nuclear localization signal (NLS) in its N-terminal region. GST-fusion proteins containing the NLS were efficiently localized to the nucleus, establishing nuclear targeting as a functional property of the NLS.\",\n      \"method\": \"cDNA cloning, bacteriophage expression library screening for kinase activity, GST-fusion nuclear localization assay, transient transfection in COS-1 cells\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical assay (kinase activity) plus subcellular localization experiment; single lab, two orthogonal methods\",\n      \"pmids\": [\"9427565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TLK2 amplification and overexpression mechanistically impairs Chk1/Chk2-induced DNA damage checkpoint signaling, leading to a G2-M checkpoint defect, delayed DNA repair, and increased chromosomal instability (CIN). TLK2 overexpression also modestly sensitizes breast cancer cells to DNA-damaging agents.\",\n      \"method\": \"TLK2 overexpression/knockdown in breast cancer cell lines, G2-M checkpoint assays, DNA damage signaling (Chk1/2 phosphorylation), DNA repair kinetics, irradiation/doxorubicin sensitivity assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based loss- and gain-of-function with defined checkpoint phenotype; single lab, multiple orthogonal readouts\",\n      \"pmids\": [\"27489360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Loss-of-function mutations in TLK2 act through haploinsufficiency, as demonstrated in cell lines from affected individuals, establishing the mechanistic basis for the associated neurodevelopmental syndrome.\",\n      \"method\": \"Cell line analysis from affected individuals, functional assessment of mutation effect on TLK2 activity\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — loss-of-function mechanism asserted from cell lines but abstract provides limited methodological detail; single study\",\n      \"pmids\": [\"29861108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TLK2 is a substrate of the circadian E3 ligase complex SCFFBXL3+CRY1/2: both CRY1 and CRY2 recruit TLK2 to SCFFBXL3, and TLK2 kinase activity is required for this interaction. Overexpression of CRY1/2 decreases TLK2 protein abundance, while genetic deletion of CRY1/2 enhances it, demonstrating CRY-modulated ubiquitin-mediated turnover of TLK2.\",\n      \"method\": \"Affinity purification mass spectrometry (APMS), CRY1/2 overexpression and genetic deletion, TLK2 protein abundance measurements\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — APMS substrate identification combined with genetic gain- and loss-of-function validation of protein abundance; single lab, two orthogonal approaches\",\n      \"pmids\": [\"30655559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Disease-associated TLK2 missense variants (p.Asp551Gly and p.Ser617Leu) strongly impair TLK2 kinase activity. Proximity interaction (BioID) mapping revealed TLK2 interacts with chromatin remodeling factors CHD7, CHD8, BRD4, and NACC1. Cells harboring p.Asp551Gly show a more relaxed chromatin state and increased susceptibility to DNA damage.\",\n      \"method\": \"BioID spatial proteomics (proximity ligation), in vitro kinase activity assay of TLK2 variants, single-cell gel electrophoresis (comet assay) for DNA damage, chromatin accessibility analysis\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct kinase activity assay plus BioID interactome and functional chromatin/DNA damage readout; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"33323470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TLK1 and TLK2 undergo hyper-autophosphorylation at their N-termini, mediated at least in part by homo- or hetero-dimerization. This hyper-autophosphorylation masks a conserved non-canonical PIP box at the N-terminus, negatively regulating TLK2 recruitment to DNA damage sites. Mutation of the PIP box abolishes TLK1/2 recruitment to DNA damage foci, establishing the PIP box–PCNA interaction as the mechanism for chromatin recruitment.\",\n      \"method\": \"In vitro autophosphorylation assays, PIP-box mutagenesis, PCNA co-immunoprecipitation, live-cell imaging of recruitment to DNA damage sites\",\n      \"journal\": \"Nucleic acids research (also preprint in bioRxiv)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro biochemical assays combined with mutagenesis and direct damage-site recruitment imaging; peer-reviewed and preprint versions independently described\",\n      \"pmids\": [\"39727191\", \"38712247\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TLK2 functions as a key regulator of chromatin loop formation during cancer stemness transitions. Mechanistically, TLK2 phosphorylates DYNLL1 (LC8), enhancing DYNLL1 interaction with CTCF and promoting CTCF-cohesin hub formation at the KLF4 locus.\",\n      \"method\": \"CRISPR screen using engineered live-cell CTCF-cohesin contact reporters, phosphorylation assays of DYNLL1 by TLK2, Co-IP of DYNLL1–CTCF interaction, chromatin loop analysis at KLF4 locus, in vivo mouse models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — CRISPR functional screen combined with direct substrate phosphorylation assay and protein interaction validation by Co-IP; single study with multiple orthogonal methods\",\n      \"pmids\": [\"41120304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Calcium overload increases TLK2 expression, multimerization, and phosphorylation, enhancing its kinase activity in neurons. Elevated TLK2 activity triggers nuclear envelope (NE) rupture, nuclear enlargement, multinucleation, and cell cycle reentry markers. A protein complex involving TLK2, dynein light chain LC8, and myosin IIA was linked to NE disruption. TLK2 inhibition (RNAi or small-molecule inhibitor) reduces neuronal death in this context.\",\n      \"method\": \"RNA interference, small-molecule TLK2 inhibition, overexpression, live-cell imaging of nuclear envelope rupture, co-immunoprecipitation (TLK2–LC8–myosin IIA complex), mouse glaucoma model with retinal ganglion cell degeneration readout\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (RNAi, small-molecule inhibition, overexpression, complex identification by Co-IP, in vivo model) in single peer-reviewed study\",\n      \"pmids\": [\"40210858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TLK2 knockdown in gastric cancer cells suppresses amino acid synthesis by downregulating the mTORC1 pathway and ASNS expression. TLK2 directly interacts with ATF4 (a transcription factor of ASNS) and promotes its expression. mTORC1 directly interacts with ASNS protein and inhibits its ubiquitination-mediated degradation.\",\n      \"method\": \"IP-MS (interactome identification), TLK2 knockdown/overexpression, mTORC1 pathway analysis, co-immunoprecipitation (TLK2–ATF4; mTORC1–ASNS), ubiquitination assays, fostamatinib TLK2 kinase inhibition\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and IP-MS with functional pathway validation; single lab, multiple methods\",\n      \"pmids\": [\"37542132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TLK2 overexpression in glioblastoma activates SRC signaling, driving cell growth, migration, invasion, and EMT. Inhibition of SRC signaling with saracatinib reverses TLK2-mediated migration and invasion, placing TLK2 upstream of SRC pathway in glioblastoma.\",\n      \"method\": \"TLK2 overexpression/knockdown in glioblastoma cells, cell migration/invasion assays, SRC pathway inhibition with saracatinib\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological epistasis with single inhibitor, no direct biochemical interaction demonstrated; single lab, single method for pathway placement\",\n      \"pmids\": [\"30207834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In postmitotic neurons, TLK2 undergoes nuclear export upon neuronal differentiation, generating a predominantly cytoplasmic pool. This is mediated by two mechanisms: nuclear export of full-length TLK2 and increased expression of TLK2 splice variants lacking the NLS. Acute stimuli mimicking synaptic activity are sufficient to trigger nuclear export of TLK2, establishing activity-driven nucleocytoplasmic shuttling as a neuronal-specific regulatory mechanism.\",\n      \"method\": \"In situ hybridization with splice-specific probes in mouse brain sections, subcellular fractionation and immunostaining in rat neuroblastoma cells during differentiation, live imaging of TLK2 localization after synaptic stimulation\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with functional differentiation context and splice variant characterization; single lab, two orthogonal localization methods\",\n      \"pmids\": [\"42023051\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TLK2 is a nuclear-localized serine/threonine kinase (with activity-driven cytoplasmic redistribution in neurons) that autophosphorylates at its N-terminus via homo/heterodimerization, masking a PIP box to negatively regulate PCNA-dependent recruitment to DNA damage sites; it is ubiquitinated and turned over via the SCFFBXL3+CRY1/2 E3 ligase complex (requiring TLK2 kinase activity for substrate recruitment); TLK2 phosphorylates DYNLL1 to drive CTCF-cohesin chromatin loop formation; TLK2 overexpression impairs Chk1/2-mediated G2-M checkpoint signaling causing chromosomal instability; and calcium overload activates TLK2 kinase activity through multimerization, forming a complex with LC8 and myosin IIA that ruptures the nuclear envelope in a distinct neuronal death pathway.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TLK2 is a nuclear serine/threonine protein kinase that couples its catalytic activity to chromatin regulation, DNA damage responses, and cell-fate decisions [#0, #5]. Its recruitment to chromatin is gated by autoregulation: TLK2 hyper-autophosphorylates its N-terminus through homo- and hetero-dimerization with TLK1, masking a non-canonical PIP box that mediates PCNA-dependent recruitment to DNA damage sites [#5]. Functionally, TLK2 organizes higher-order chromatin by phosphorylating DYNLL1 (LC8), which enhances DYNLL1–CTCF binding and promotes CTCF–cohesin loop/hub formation at the KLF4 locus during cancer stemness transitions [#6], and it associates in proximity with the chromatin remodelers CHD7, CHD8, BRD4, and NACC1 [#4]. TLK2 abundance is controlled by ubiquitin-mediated turnover through the circadian E3 ligase SCFFBXL3 via CRY1/2, a recruitment that depends on TLK2 kinase activity [#3]. Through these activities TLK2 enforces genome stability, since its overexpression impairs Chk1/Chk2 G2-M checkpoint signaling, delays repair, and drives chromosomal instability [#1], while loss-of-function and kinase-dead missense variants relax chromatin and increase DNA damage susceptibility, acting through haploinsufficiency to cause a neurodevelopmental syndrome [#2, #4]. In neurons, TLK2 is regulated by activity-driven nucleocytoplasmic shuttling [#10], and calcium overload activates TLK2 via multimerization to form a complex with LC8 and myosin IIA that ruptures the nuclear envelope in a degenerative death pathway [#7].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established TLK2's basic identity, answering whether the gene encodes a functional kinase and where it acts by identifying catalytic activity and a functional nuclear localization signal.\",\n      \"evidence\": \"cDNA cloning with kinase-activity expression screening and GST-fusion nuclear localization assay in COS-1 cells\",\n      \"pmids\": [\"9427565\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No substrates identified\", \"No physiological pathway context\", \"NLS function shown only for an isolated GST fusion\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked TLK2 dosage to genome maintenance by showing that its overexpression disrupts checkpoint signaling, framing TLK2 as a driver of chromosomal instability in cancer.\",\n      \"evidence\": \"Gain- and loss-of-function in breast cancer lines with G2-M checkpoint, Chk1/2 phosphorylation, repair kinetics, and DNA-damage sensitivity readouts\",\n      \"pmids\": [\"27489360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase substrate in the checkpoint pathway not identified\", \"Mechanism connecting TLK2 to Chk1/2 unresolved\", \"Single cancer-cell context\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the genetic mechanism of TLK2-associated disease, showing that loss-of-function variants cause a neurodevelopmental syndrome through haploinsufficiency.\",\n      \"evidence\": \"Functional assessment of patient-derived cell lines carrying TLK2 mutations\",\n      \"pmids\": [\"29861108\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Limited methodological detail in the source\", \"Molecular pathway linking haploinsufficiency to neurodevelopmental phenotype not defined\", \"Single study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed TLK2 upstream of an oncogenic signaling axis by showing it activates SRC to drive glioblastoma migration and invasion.\",\n      \"evidence\": \"Overexpression/knockdown with migration/invasion assays and SRC inhibition by saracatinib\",\n      \"pmids\": [\"30207834\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Pharmacological epistasis only — no direct biochemical link to SRC\", \"No demonstrated phosphorylation target\", \"Single inhibitor used for pathway placement\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified how TLK2 protein levels are controlled, showing it is a kinase-activity-dependent substrate of the circadian SCFFBXL3+CRY1/2 ubiquitin ligase.\",\n      \"evidence\": \"APMS substrate identification plus CRY1/2 overexpression and genetic deletion with TLK2 abundance measurements\",\n      \"pmids\": [\"30655559\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitination sites on TLK2 not mapped\", \"Physiological consequence of circadian TLK2 oscillation not tested\", \"Whether kinase activity drives autoturnover unexplored\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected disease variants to molecular dysfunction by showing missense mutations abolish kinase activity and that TLK2 sits in a chromatin-remodeler interactome controlling chromatin compaction.\",\n      \"evidence\": \"In vitro kinase assays of variants, BioID proximity interactome, comet assay, and chromatin accessibility analysis\",\n      \"pmids\": [\"33323470\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrates among CHD7/CHD8/BRD4/NACC1 not established\", \"Whether proximity partners are phosphorylated by TLK2 unknown\", \"Causal chain from kinase loss to chromatin relaxation incomplete\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved the mechanism gating TLK2 chromatin recruitment, showing autophosphorylation masks a PIP box required for PCNA-dependent recruitment to damage sites.\",\n      \"evidence\": \"In vitro autophosphorylation assays, PIP-box mutagenesis, PCNA Co-IP, and live-cell imaging of damage-site recruitment\",\n      \"pmids\": [\"39727191\", \"38712247\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of de-repression at damage sites not defined\", \"Downstream chromatin substrates at damage foci not identified\", \"Relative roles of TLK1 vs TLK2 dimers unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined a direct catalytic output of TLK2 in genome architecture, showing it phosphorylates DYNLL1 to promote CTCF-cohesin loop formation governing cancer stemness.\",\n      \"evidence\": \"CRISPR screen with live-cell CTCF-cohesin reporters, DYNLL1 phosphorylation assays, DYNLL1–CTCF Co-IP, loop analysis at KLF4, and mouse models\",\n      \"pmids\": [\"41120304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"DYNLL1 phosphosite(s) not detailed in this synthesis\", \"Generality beyond the KLF4 locus unclear\", \"Link between this loop function and DNA-damage role unexplored\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered a pathological neuronal function, showing calcium-driven TLK2 multimerization and activity form an LC8–myosin IIA complex that ruptures the nuclear envelope to drive neuronal death.\",\n      \"evidence\": \"RNAi, small-molecule inhibition, overexpression, live imaging of NE rupture, TLK2–LC8–myosin IIA Co-IP, and a mouse glaucoma RGC degeneration model\",\n      \"pmids\": [\"40210858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrate driving NE rupture not identified\", \"How calcium triggers multimerization mechanistically unknown\", \"Relationship to TLK2's chromatin functions unresolved\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Established neuron-specific spatial regulation of TLK2, showing differentiation and synaptic activity drive its nuclear export and NLS-lacking splice variants generate a cytoplasmic pool.\",\n      \"evidence\": \"Splice-specific in situ hybridization in mouse brain, subcellular fractionation/immunostaining during neuroblastoma differentiation, and live imaging after synaptic stimulation\",\n      \"pmids\": [\"42023051\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytoplasmic substrates of exported TLK2 not identified\", \"Export machinery not defined\", \"Functional consequence of activity-driven shuttling untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Implicated TLK2 in metabolic control, showing it interacts with ATF4 to promote ASNS expression and amino-acid synthesis via mTORC1 in gastric cancer.\",\n      \"evidence\": \"IP-MS, knockdown/overexpression, TLK2–ATF4 and mTORC1–ASNS Co-IP, ubiquitination assays, and TLK2 kinase inhibition\",\n      \"pmids\": [\"37542132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TLK2 phosphorylates ATF4 not shown\", \"Direct vs indirect mTORC1 regulation unresolved\", \"Single cancer-cell context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TLK2's distinct activities — DNA-damage recruitment, CTCF-cohesin looping, circadian turnover, neuronal nuclear-envelope rupture, and metabolic signaling — are coordinated by a single kinase, and what its full substrate repertoire is, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"A unifying substrate logic across contexts is undefined\", \"Tissue-specific regulation of which function dominates is unknown\", \"Structural basis of activity-dependent multimerization vs dimerization unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [10, 7]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [5, 1]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"complexes\": [\n      \"SCFFBXL3-CRY1/2 E3 ligase (substrate)\",\n      \"TLK2-LC8-myosin IIA complex\"\n    ],\n    \"partners\": [\n      \"DYNLL1\",\n      \"PCNA\",\n      \"CRY1\",\n      \"CRY2\",\n      \"CHD7\",\n      \"CHD8\",\n      \"BRD4\",\n      \"ATF4\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}